Autoimmune hepatitis: Diagnostic and therapeutic up-to-date;Hépatites auto-immunes: Actualités diagnostiques et thérapeutiques

Revue de Medecine Interne

Volumn 31, Issue 9, 2010, Pages 606-614

  Corpechot, C ^a   Chazouilleres O ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Autoantibodies; Autoimmunity; Hepatitis; Immunosuppressors

Indexed keywords

AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; IMMUNOGLOBULIN; LIVER KIDNEY MICROSOME 1 ANTIBODY; MERCAPTOPURINE; MICROSOME ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SMOOTH MUSCLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; AUTOIMMUNE HEPATITIS; AUTOIMMUNE HEPATITIS TYPE 1; AUTOIMMUNE HEPATITIS TYPE 2; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIVER BIOPSY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; RECURRENCE RISK; RELAPSE; REMISSION; SCORING SYSTEM; SHORT SURVEY; TREATMENT INDICATION; TREATMENT WITHDRAWAL;

HEPATITIS, AUTOIMMUNE; HUMANS;

EID: 84755161501     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2009.05.015     Document Type: Short Survey

References (48)

1. Manns M.P., Strassburg C.P. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001, 120:1502-1517.
2. Krawitt E.L. Autoimmune hepatitis. N Engl J Med 2006, 354:54-66.
3. Schramm C., Kanzler S., zum Buschenfelde K.H., Galle P.R., Lohse A.W. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001, 96:1587-1591.
4. Boberg K.M., Aadland E., Jahnsen J., Raknerud N., Stiris M., Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998, 33:99-103.
5. Kessler W.R., Cummings O.W., Eckert G., Chalasani N., Lumeng L., Kwo P.Y. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004, 2:625-631.
6. Czaja A.J., Homburger H.A. Autoantibodies in liver disease. Gastroenterology 2001, 120:239-249.
7. Meda F., Zuin M., Invernizzi P., Vergani D., Selmi C. Serum autoantibodies: a road map for the clinical hepatologist. Autoimmunity 2008, 41:27-34.
8. Pratt D.S., Fawaz K.A., Rabson A., Dellelis R., Kaplan M.M. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997, 113:664-668.
9. Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., Scheuer P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994, 19:1513-1520.
10. Ben-Ari Z., Czaja A.J. Autoimmune hepatitis and its variant syndromes. Gut 2001, 49:589-594.
11. Johnson P.J., McFarlane I.G. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993, 18:998-1005.
12. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
13. Hennes E.M., Zeniya M., Czaja A.J., Pares A., Dalekos G.N., Krawitt E.L., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
14. Johanet C., Dubel L., Chazouilleres O. Autoantibodies in hepatology. Pathol Biol 1999, 47:997-1005.
15. Manns M.P., Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006, 43:S132-S144.
16. Fusconi M., Cassani F., Zauli D., Lenzi M., Ballardini G., Volta U., et al. Anti-actin antibodies: a new test for an old problem. J Immunol Methods 1990, 130:1-8.
17. Wies I., Brunner S., Henninger J., Herkel J., Kanzler S., Meyer zum Buschenfeld K.H., et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000, 355:1510-1515.
18. Ballot E., Homberg J.C., Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 autoimmune hepatitis. J Hepatol 2000, 33:208-215.
19. Obermayer-Straub P., Perheentupa J., Braun S., Kayser A., Barut A., Loges S., et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology 2001, 121:668-677.
20. Martini E., Abuaf N., Cavalli F., Durand V., Johanet C., Homberg J.C. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988, 8:1662-1666.
21. Chazouilleres O. Diagnosis of primary sclerosing cholangitis - autoimmune hepatitis overlap syndrome: to score or not to score?. J Hepatol 2000, 33:661-663.
22. Chazouilleres O., Wendum D., Serfaty L., Montembault S., Rosmorduc O., Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28:296-301.
23. Chazouilleres O., Wendum D., Serfaty L., Rosmorduc O., Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006, 44:400-406.
24. Czaja A.J., Freese D.K. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002, 36:479-497.
25. Cook G.C., Mulligan R., Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971, 40:159-185.
26. Murray-Lyon I.M., Stern R.B., Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973, 1:735-737.
27. Soloway R.D., Summerskill W.H., Baggenstoss A.H., Geall M.G., Gitnick G.L., Elveback I.R., et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972, 63:820-833.
28. Summerskill W.H., Korman M.G., Ammon H.V., Baggenstoss A.H. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975, 16:876-883.
29. Czaja A.J., Rakela J., Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988, 95:448-453.
30. Verma S., Gunuwan B., Mendler M., Govindrajan S., Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004, 99:1510-1516.
31. Ichai P., Duclos-Vallee J.C., Guettier C., Hamida S.B., Antonini T., Delvart V., et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007, 13:996-1003.
32. Langley P.G., Underhill J., Tredger J.M., Norris S., McFarlane I.G. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002, 37:441-447.
33. Stellon A.J., Davies A., Compston J., Williams R. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology 1985, 89:1078-1083.
34. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis. Arthritis Rheum 2001;44:1496-503.
35. Czaja A.J., Wolf A.M., Baggenstoss A.H. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981, 80:687-692.
36. Roberts S.K., Therneau T.M., Czaja A.J. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996, 110:848-857.
37. Wang K.K., Czaja A.J., Beaver S.J., Go V.L. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989, 10:39-43.
38. Czaja A.J., Davis G.L., Ludwig J., Taswell H.F. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984, 4:622-627.
39. Kanzler S., Gerken G., Lohr H., Galle P.R., Meyer zum Buschenfeld K.H., Lohse A.W. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001, 34:354-355.
40. Manns M.P., Bahr M.J., Woynarowski M., Kreisel W., Oren R., Günther R., et al. Budesonide 3mg tid is superior to prednisone in combination with azathioprine in the treatment of autoimmune hepatitis. J Hepatol 2008, 48:S369-S370.
41. Manns M., Woynarowski M., Kreisel W., Oren R., Rust C., Hultcrantz R., et al. Budesonide 3mg BID in combination with azathioprine as maintenance treatment of autoimmune hepatitis - Final results of a large multicenter international trial. Hepatology 2008, 48:376A-377A.
42. Geier A., Gartung C., Dietrich C.G., Wasmuth H.E., Reinartz P., Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003, 9:2681-2685.
43. Fernandes N.F., Redeker A.G., Vierling J.M., Villamil F.G., Fong T.L. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999, 94:241-248.
44. Debray D., Maggiore G., Girardet J.P., Mallet E., Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999, 135:111-114.
45. Sharzehi K., Brown K., Sherbondy M.A. The use of mycophenolate mofetil in the treatment of autoimmune hepatitis in patients refractory to or intolerant of conventional treatment. Hepatology 2007, 46:555A-556A.
46. Czaja A.J., Carpenter H.A., Lindor K.D. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999, 30:1381-1386.
47. Czaja A.J., Menon K.V., Carpenter H.A. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002, 35:890-897.
48. Buchel E., Van Steenbergen W., Nevens F., Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 2002, 97:3160-3165.